Responses
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
